United Therapeutics Corp. is discontinuing development of esuberaprost (beraprost 314d), an oral prostacyclin analogue, after its phase III Beat study in patients with pulmonary arterial hypertension (PAH) failed to meet the primary endpoint.
Initial data from the highest dose of the phase I/II Alta trial testing Sangamo Therapeutics Inc. and Pfizer Inc.'s SB-525 hemophilia A gene therapy look promising.
Initial data from the highest dose of the phase I/II Alta trial testing Sangamo Therapeutics Inc. and Pfizer Inc.'s SB-525 hemophilia A gene therapy look promising.
Quarter after quarter, analysts have been pestering management on Biogen Inc.'s conference calls about whether there would be an interim analysis for the phase III program testing its Alzheimer's disease drug aducanumab.
Quarter after quarter, analysts have been pestering management on Biogen Inc.'s conference calls about whether there would be an interim analysis for the phase III program testing its Alzheimer's disease drug aducanumab.
The use of contract research organizations (CROs) by drug developers has continued to grow at an 8 percent clip annually since 2010, reaching an estimated $86 billion in 2018, according to a new report from the Tufts Center for the Study of Drug Development (CSDD).
With shares down more than 25 percent since its $5 IPO in October, Phasebio Pharmaceuticals Inc. saw its fortunes reverse with the help of phase I data for its reversal agent, PB-2452.
The use of contract research organizations (CROs) by drug developers has continued to grow at an 8 percent clip annually since 2010, reaching an estimated $86 billion in 2018, according to a new report from the Tufts Center for the Study of Drug Development (CSDD).
After Gtx Inc.'s only clinical candidate, selective androgen receptor modulator (SARM) enobosarm, failed to improve stress urinary incontinence in postmenopausal women, the company underwent a review of strategic alternatives.
With positive phase III data in hand from its next-generation corrector, VX-659, Vertex Pharmaceuticals Inc. was in a no-lose situation as it released data from the cystic fibrosis (CF) phase III studies for its other next-generation corrector, VX-445.
